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Summary
Estrogen (E2)-responsive peripheral tissues, such as skeletal
muscle, may suffer from hormone deficiency after menopause
potentially contributing to the aging of muscle. However,
recently E2 was shown to be synthesized by muscle and its
systemic and intramuscular hormone levels are unequal. The
objective of the study was to examine the association between
intramuscular steroid hormones and muscle characteristics in
premenopausal women (n = 8) and in postmenopausal monozy-
gotic twin sister pairs (n = 16 co-twins from eight pairs) discor-
dant for the use of E2-based hormone replacement. Isometric
skeletal muscle strength was assessed by measuring knee exten-
sion strength. Explosive lower body muscle power was assessed
as vertical jump height. Due to sequential nature of enzymatic
conversion of biologically inactive dehydroepiandrosterone
(DHEA) to testosterone (T) and subsequently to E2 or dihydrotes-
tosterone (DHT), separate linear regression models were used to
estimate the association of each hormone with muscle charac-
teristics. Intramuscular E2, T, DHT, and DHEA proved to be
significant, independent predictors of strength and power
explaining 59–64% of the variation in knee extension strength
and 80–83% of the variation of vertical jumping height in women
(P < 0.005 for all models). The models were adjusted for age,
systemic E2, and total body fat mass. The statistics used took into
account the lack of statistical independence of twin sisters.
Furthermore, muscle cells were shown to take up and actively
synthesize hormones. Present study suggests intramuscular sex
steroids to associate with strength and power regulation in
female muscle providing novel insight to the field of muscle
aging.
Key words: intracrine organ; steroidogenesis; muscle perfor-
mance; local hormone synthesis; muscle steroids.
Introduction
Aging, in general, is associated with gradual decrements in tissue and
organ functions. In women, menopause characterized by the loss of
ovarian function represents an aging process that leads to changes in the
systemic steroid hormone profile from a regularly fluctuating estrogen
cycle to very low and constant levels. This decrease in systemic estrogen
may, however, have tissue-specific effects on estrogen-responsive tissues
such as skeletal muscle (Wend et al., 2012). Premenopausal women tend
to have better muscle properties than postmenopausal women while the
use of postmenopausal hormone replacement therapy (HRT) partially
prevents aging-related decrements or even improves muscle function
during the early years of menopause (Sipil€a et al., 2001; Lowe et al.,
2010). We have previously shown that the use of HRT, which increases
systemic estrogen levels, helps to maintain better body and muscle
composition and functionby influencingmuscle gene expression (P€oll€anen
et al., 2010; Ronkainen et al., 2010). However, systemic estrogen
concentration measured in the serum cannot be directly taken as an
estimate of the hormone content of the tissue (P€oll€anen et al., 2011). It is
generally accepted that aromatization of testosterone (T) to 17b-estradiol
(E2) by the aromatase cytochrome P450 enzyme (called aromatase here
after) occurs in skeletal muscle (Longcope et al., 1978). More recently,
Aizawa et al. (2007) showed that rat muscle cells are able to take up the
precursor hormone dehydroepiandrosterone (DHEA) and use it to synthe-
size biologically active sex steroid hormones: T and E2. They also showed
that acute exercise and endurance training induces steroidogenesis in rat
skeletal muscle (Aizawa et al., 2010, 2011) while Vingren et al. (2008)
found no differences in human muscular steroidogenesis in response to a
single bout of resistance exercise. Recently, Sato et al. (2014a) showed that
resistance training restores muscle androgen levels in older men. Our
previous study showed differences in systemic and intramuscular hormone
concentrations parallel to differences in thigh muscle size, performance,
and quality in healthy pre- and postmenopausal women not using HRT
(P€oll€anen et al., 2011). Currently, there are no studies which have
investigated the effects of intramuscular steroid hormone levels or local
steroidogenesis on muscle properties or performance in women with
different hormonal status. The aim of this study was to investigate the
associations between intramuscular sex steroid hormones and muscle
properties in different menopausal backgrounds. The unique design with
postmenopausal HRT discordant twin pairs reinforced with additional
group of premenopausal women was used. In addition, this current study
investigates in vitro the ability of muscle cells to take up and synthesize sex
steroid hormones and to transcriptionally respond to hormonal stimuli.
Results
Premenopausal women have better muscle properties than
postmenopausal women
This study is a cross-sectional co-twin case-controlled study using
postmenopausal monozygotic (MZ) twin pairs (n = 16 co-twins from
eight pairs) with additional premenopausal control group (n = 8).
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Premenopausal women (aged 32  2 years) did not use hormonal
preparations (P€oll€anen et al., 2011). Postmenopausal MZ twin pairs (aged
58  2 years) were discordant for the use of E2-based HRT (Ronkainen
et al., 2009). Characteristics of the study participants are presented in the
Table 1. There were no differences in anthropometry, body composition
or the level of physical activity between the study groups. However,
premenopausal women were stronger and more powerful and had larger
muscles than postmenopausal women. Premenopausal women’s knee
extension strength was 31.0% higher compared to HRT users and 33.5%
higher compared to nonusers (P = 0.008 and 0.010, respectively).
According to vertical jumping height measurement, premenopausal
women had 60.0% higher muscle power than postmenopausal HRT
users (P = 0.001) and 95.5% higher power than postmenopausal
nonusers (P < 0.001). In addition, premenopausal women had 9.5%
larger thigh muscle cross-sectional area (CSA) than postmenopausal HRT
users (not significant difference) and 15.1% larger thigh CSA than
nonusers (P = 0.034). Postmenopausal HRT users had significantly
greater muscle power than their nonusing co-sisters (22.2%, P = 0.006).
Intramuscular hormone concentrations and systemic
hormone levels are different in pre- and postmenopausal
women
Results regarding systemic and intramuscular sex steroid hormones are
presented in Fig. 1, and results concerning other relevant systemic
hormones are summarized in Table 1. Premenopausal women had
significantly higher systemic E2 concentration than postmenopausal HRT
users (P = 0.045) and nonusers (P = 0.006), while the difference between
HRT users and nonusers was at the borderline of significance (P = 0.055).
Systemic concentrations of T and dihydrotestosterone (DHT) were signif-
icantly higher in premenopausal as compared to postmenopausal nonusers
(P = 0.045 and 0.017, respectively), but there were no significant
differences when premenopausal women were compared to postmeno-
pausal HRT users orwhenHRT userswere compared to nonusing co-sisters.
No significant differences were observed in systemic sulfated DHEA
(DHEAS) concentration between any of the group comparisons. The
hormone concentrations measured from muscle samples (Fig. 1E–H) did
not, however, reflect the systemic concentrations (Fig. 1A–D). There were
significant differences between the groups only for intramuscular DHT
(Fig. 1G) that was lower in premenopausal women when compared to
both postmenopausal groups (P = 0.048 for HRT users and P = 0.041 for
nonusers). Surprisingly, therewere virtually no differences between groups
in the intramuscular E2 and T although systemic differences, especially for
E2, were observed. In particular, the use of E2-containingHRT did not affect
the intramuscular E2 concentration in the HRT discordant MZ twins.
Furthermore, there were strong intraclass correlation between co-sisters
regarding the intramuscular concentrations of E2 (r = 0.931, P = 0.001),
DHT (r = 0.818, P = 0.013), andDHEA (r = 0.765, P = 0.028), suggesting
that intramuscular steroidogenesis is more subject to genetic than systemic
control. One premenopausal participant had exceptionally high hormone
concentrations inhermuscle sample (Fig. 1E–H). Excluding this outlier from
the statistical testing did not change the significance of the results
presented above except that differences between the premenopausal
group and the postmenopausal nonusers and HRT users were stronger
(P < 0.001 for both comparisons). Therefore, we did not exclude this
participant from any of the analyses performed in this study.
Intramuscular sex steroid levels are associated with muscle
performance
Linear regression analyses were performed to evaluate the association
between intramuscular sex steroid hormones and muscle characteristics
(Table 2, 3 and S1). As the synthesis of steroid hormones proceeds
sequentially from the biologically inactive precursor DHEA to T and
further to E2 or DHT, separate models were developed for each
hormone. According to the raw models, intramuscular E2, T, and DHEA,
but not DHT, were significantly associated with muscle strength and
power, explaining 36–39% of the variation in knee extension strength
(Table 2) and 37–45% of the variation in vertical jumping height
(Table 3). Intramuscular hormones were not associated with thigh
Table 1 Characteristics of the study participants
Premenopausal
women (n = 8)
Postmenopausal
HRT users (n = 8)
Postmenopausal
nonusers (n = 8)
P-values
Pre- vs. HRT users Pre- vs. nonusers HRT vs. nonusers
Age (years) 32  2 58  2 58  2
MET index 4.8  3.5 8.4  8.1 4.4  2.4 0.271 0.799 0.142
Body composition
Height (cm) 164.6  3.7 162.6  4.5 162.1  3.8 0.350 0.208 0.240
Weight (kg) 69.5  10.7 66.3  8.7 69.8  14.1 0.522 0.971 0.307
LBM (kg) 45.5  3.5 43.5  3.6 42.8  4.6 0.277 0.201 0.518
Fat mass (kg) 21.3  8.3 19.9  6.0 24.1  9.5 0.696 0.552 0.066
Muscle performance
KES (N) 584.2  106.8 446.1  66.3 437.7  90.6 0.008 0.010 0.685
VjH (cm) 26.4  6.1 16.5  3.0 13.5  4.4 0.001 <0.001 0.006
Thigh CSA (cm2) 106.1  11.4 96.9  12.1 92.2  12.2 0.143 0.034 0.171
Systemic variables
LH (IU L1) 12.8  12.6 25.4  5.0 28.6  6.0 0.020 0.006 0.273
FSH (IU L1) 6.2  2.7 66.3  24.3 95.6  11.7 <0.001 <0.001 0.010
SHBG (nmol L1) 49.3  16.8 72.3  30.7 47.1  13.1 0.086 0.777 0.019
FSH, follicle-stimulating hormone; KES, knee extension strength; LH, luteinizing hormone; LMB, lean body mass; MET index, metabolic equivalent index; SHBG, serum
hormone-binding globulin; Thigh CSA, cross-sectional area of lean thigh muscle compartment; VjH, vertical jumping height.
Statistically significant P-values are highlighted by bolding the letters.
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Fig. 1 Median and distribution of systemic
(A, B, C, D) and intramuscular (E, F, G, H)
sex steroid hormone concentrations in
premenopausal women and in
postmenopausal HRT using MZ twins and
their nonusing co-sisters. For each box, the
bold central line indicates the group
median. The top and bottom edges of each
box indicate the upper and lower quartiles,
respectively. T-bars that extend from the
boxes indicate highest and lowest
observations, with the exception of outliers
marked with asterisk and ID of the
participant. Under each figure, the mean
valuesstandard deviation for each group
is presented. E2, 17b-estradiol; T,
testosterone; DHT, dihydrotestosterone;
DHEAS, dehydroepiandrosterone sulfate;
DHEA, dehydroepiandrosterone.
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muscle CSA (Table S1, Supporting information). To control for possible
confounders, models were adjusted for age, systemic E2, and total body
fat mass. According to the adjusted models, all intramuscular hormones
were significantly associated with muscle strength and power (for all
hormones P < 0.005). Intramuscular E2 explained 63%, intramuscular T
64%, intramuscular DHT 64%, and intramuscular DHEA 59% of the
variation in knee extension strength. From the variation of muscle
power, intramuscular E2 explained 83%, intramuscular T 83%, intra-
muscular DHT 80%, and intramuscular DHEA 83%.
Gene expression of aromatase and steroid hormone
receptors during in vitro differentiation of myoblasts
To assess whether human muscle cells have a potential to synthesize E2
and to activate hormone receptor-dependent signaling, the in vitro
expression of aromatase (CYP19A1 gene), the enzyme converting T to
E2, and steroid hormone receptors, including ESR1, ESR2, GPER, and
androgen receptor (AR), were measured. Human muscle progenitor cells
(myoblasts) were induced to differentiate to form multinucleated
myotubes. Differentiating cells were collected at 24-h intervals. At day
3, multinucleated myotubes are clearly visible and differentiation
continues thereafter. Interestingly, similar levels of E2 were detected in
the myoblasts at day 0 before switching to differentiation media and
throughout the following 7 days of differentiation (Fig. 2A). The
expression of measured genes was readily detectable at day 0 in
the proliferating myoblasts (Fig. 2). However, for the first few days, the
expression of aromatase (Fig. 2B) and ESR1 (Fig. 2C) was quite low and
then increasing steadily in the myotubes during differentiation of
myotubes. The peak of expression was observed at days 6–7, while the
expression of AR peaked already at day 3 (Fig. 2F).
Pre- and postmenopausal female sera modify the gene
expression of aromatase and steroid hormone receptors
After verifying that myogenic cells in our in vitro model are able to
produce E2 and its receptors, we used the same model to investigate
whether these cells are responsive to female sera with different
hormonal content. Multinucleated muscle cells (5 day myotubes) were
exposed to pre- and postmenopausal serum obtained from the same
study participants who were characterized previously (Fig. 1 and
Table 1). At day 5, half of the differentiation medium was changed to
differentiation medium supplemented with premenopausal serum,
postmenopausal serum from nonusers, or postmenopausal serum from
HRT users. Each serum pool contained equal amounts of serum from the
eight women of the respective group and was applied to the cells in
differentiation medium to deliver 10% v/v final serum concentration. To
detect both acute and later effects, serum-exposed cells were collected
6, 24, and 72 h after exposure. The prolonged exposure to all serum
pools reduced the expressions of aromatase, ESR2, GPER, and AR and
increased the expression of ESR1 (ANOVA P < 0.001 for all comparisons)
(Fig. 3). There were no significant differences in the expression of
aromatase (Fig. 3A) and AR (Fig. 3E) in the myotubes exposed to
different serum pools at any of the tested time points. At the 6-h time
point, only ESR2 showed indication for group differences being
somewhat higher in the myotubes exposed to serum from postmeno-
pausal HRT users than to serum from premenopausal women
(P = 0.054, Fig. 3C). At 24 h, the expression of ESR1 was lower in the
myotubes exposed to premenopausal serum compared to the postmen-
opausal nonuser serum exposure (P = 0.038), while at 72 h, the
expression was lower for both comparisons (pre- vs. nonuser
P = 0.025, pre- vs. HRT user P = 0.011, Fig. 3B). At the 24-h time
point, the expression of GPERwas also lower in the myotubes exposed to
the premenopausal serum compared to the postmenopausal nonuser
and HRT user serum exposure, but only the first comparison remained
statistically significant (P = 0.025, Fig. 3D).
The take up of 17b-estradiol does not induce transcriptional
changes in steroid hormone signaling-related genes in
myotubes
To investigate whether E2 alone is capable of inducing transcriptional
changes observed after exposure to the serum samples with different E2
concentrations (without possible confounding factors present in human
serum), myotubes were exposed to 10 nM E2, 100 nM E2 or mock, which
controls the possible effects of ethanol used as a solvent for E2. As with
Table 2 Linear regression models for skeletal muscle strength (knee extension
strength)
Model 1
B (SE)
Model 2
B (SE)
Model 3
B (SE)
Model 4
B (SE)
Estrogen models
Intramuscular E2 204.9 (54.6)
P = 0.002
153.1 (52.5)
P = 0.011
156.3 (55.1)
P = 0.013
189.4 (53.5)
P = 0.003
Age 3.5 (1.6)
P = 0.044
4.1 (1.4)
P = 0.012
3.6 (1.3)
P = 0.013
Systemic E2 0.04 (0.04)
P = 0.266
0.01 (0.02)
P = 0.508
Fat mass 5.7 (1.6)
P = 0.003
R2 for a model 0.362 0.493 0.500 0.628
Testosterone models
Intramuscular T 22.6 (5.9)
P = 0.002
17.8 (5.9)
P = 0.010
18.0 (6.2)
P = 0.012
19.6 (5.6)
P = 0.004
Age 3.6 (1.5)
P = 0.029
4.1 (1.4)
P = 0.010
3.8 (1.3)
P = 0.009
Systemic E2 0.04 (0.03)
P = 0.309
0.02 (0.02)
P = 0.515
Fat mass 4.8 (1.4)
P = 0.005
R2 for a model 0.389 0.535 0.540 0.637
DHT models
Intramuscular
DHT
36.4 (145.3)
P = 0.806
335.9 (100.7)
P = 0.005
335.9 (101.9)
P = 0.005
360.1 (90.0)
P = 0.001
Age 8.0 (1.7)
P < 0.001
8.3 (1.7)
P < 0.001
8.4 (1.6)
P < 0.001
Systemic E2 0.02 (0.03)
P = 0.555
0.03 (0.02)
P = 0.158
Fat mass 4.7 (1.4)
P = 0.005
R2 for a model 0.004 0.544 0.545 0.635
DHEA models
Intramuscular
DHEA
3.8 (0.9)
P = 0.001
2.9 (0.9)
P = 0.006
2.9 (0.9)
P = 0.008
3.0 (0.8)
P = 0.002
Age 3.6 (1.7)
P = 0.049
4.1 (1.5)
P = 0.018
3.9 (1.5)
P = 0.019
Systemic E2 0.1 (0.1)
P = 0.311
0.01 (0.02)
P = 0.788
Fat mass 4.1 (1.8)
P = 0.034
R2 for a model 0.372 0.508 0.514 0.586
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serum exposure, the experiments were started after 5 days of
differentiation. Myotubes were harvested after 6-, 24- and 72-h
exposure to E2. Cells readily took up E2 as shown by the increase in the
cellular concentration of E2 (Fig. 4A) and the parallel decrease in the
medium concentration of E2 (data not shown), whereas cellular T
concentration remained unchanged (Fig. 4B). There were significant
group differences in the cellular concentration of E2 at all three time
points (ANOVA P = 0.001, 0.002 and < 0.001, respectively) following
exposure to 100 nM E2. Cellular E2 concentration was significantly
upregulated already at 6 h in 100 nM E2-exposed myotubes compared
to mock (P = 0.002) and continued to be elevated at 24 h (P = 0.003)
and at 72 h (P < 0.001), while 10 nM E2 was not sufficient to increase
the cellular concentration of E2 at any time point. However, there were
no significant differences in the gene expression of aromatase, ESR1,
ESR2, GPER, or AR at any of the time points after exposure to 10 or
100 nM E2 compared to the mock-treated cells (Fig. 4C–G). Some
uniform treatment-independent differences in the gene expression
between time points were observed. There was a significant increment
in the expression of aromatase at the 72-h time point compared to 6
and 24 h (ANOVA P < 0.001). ESR1 expression was lowest at the 24-h
time point with all treatments (ANOVA P < 0.001), and ESR2 expres-
sion was highest at the 6-h time point with all treatments (ANOVA
P < 0.001).
DHEA induces steroidogenesis in myotubes
Finally, we examined whether the precursor hormone DHEA is taken up
into the myotubes in culture and further processed to T or E2. After
5 days of differentiation, myotubes were exposed to 100 nM DHEA,
500 nM DHEA or mock for 6, 24 and 72 h. Myotubes readily took up
DHEA into the cells as shown by the increase in the cellular concentration
of DHEA (Fig. 5A). There were significant group differences at all time
points (ANOVA P = 0.001, 0.003 and 0.002, respectively). Cellular DHEA
concentration was significantly upregulated already at 6 h in 500 nM
DHEA-exposed myotubes when compared to mock (P = 0.002) and
continued to be elevated at 24 h (P = 0.004) and at 72 h (P = 0.004),
while 100 nM DHEA was not sufficient to increase cellular concentration
of DHEA at any time point. Interestingly, the cellular concentrations of T
and E2 also increased in response to the DHEA treatment, indicating that
their synthesis from DHEA was induced. However, the differences in E2
concentration did not reach statistical significance (Fig. 5B). Cellular T
concentration was significantly different at 6- and 24-h time points, but
not at 72 h (ANOVA P = 0.007, 0.027 and 0.144, respectively; Fig. 5C).
In addition, the gene expression of aromatase was statistically signifi-
cantly upregulated after 72-h exposure to 500 nM DHEA (P = 0.13),
while no significant differences in the gene expression of ESR1, ESR2,
GPER, or AR were observed (Fig 5D–H).
Discussion
In the present study, we show that premenopausal women have larger
thigh muscles with better performance (strength and power) than
postmenopausal women although differences were more prominent
when comparing to nonusers than to users of estrogen-containing HRT.
This may be explained by protective actions of HRT, which elevate
systemic E2 to levels closer to those observed in premenopausal women.
However, the systemic steroid hormone levels were shown not to be
related to intramuscular hormone levels. More importantly, intramuscu-
lar sex steroid hormones were strongly associated with muscle strength
and power. From the measured intramuscular hormones E2, T, and
DHEA were all shown to be independent predictors of knee extension
strength and vertical jumping height. The final models adjusted for age,
systemic E2, and body fat mass showed a highly significant association of
intramuscular E2, T, DHT, and DHEA with muscle strength and power,
but not with muscle size. This finding adds new insight into our current
knowledge gained concerning the effects of systemic steroid hormones
on aging-related changes in skeletal muscle properties in women
(recently summarized in Sipil€a et al., 2013; Tiidus et al., 2013). Previous
studies have shown age-related reductions in systemic hormone
concentrations to occur in parallel with the decline in muscle perfor-
mance (Phillips et al., 1993) and that postmenopausal use of HRT is
associated with better muscle performance (Sipil€a et al., 2001; Ronkai-
nen et al., 2009; Finni et al., 2011). Age-related muscle decline and the
potential benefit from the use of HRT were also evident in the current
study, but despite the age-related differences in systemic hormone
concentrations, the intramuscular E2, T, and DHEA concentrations were
Table 3 Linear regression models for skeletal muscle power (vertical jumping
height)
Model 1
B (SE)
Model 2
B (SE)
Model 3
B (SE)
Model 4
B (SE)
Estrogen models
Intramuscular E2 15.6 (3.1)
P < 0.001
10.4 (2.3)
P < 0.001
9.9 (1.6)
P < 0.001
8.4 (1.6)
P < 0.001
Age 0.4 (0.1)
P < 0.001
0.3 (0.1)
P = 0.001
0.3 (0.1)
P = 0.002
Systemic E2 0.01 (0.01)
P = 0.014
0.01 (0.01)
P = 0.056
Fat mass 0.3 (0.1)
P < 0.001
R2 for a model 0.454 0.739 0.772 0.830
Testosterone models
Intramuscular T 1.5 (0.3)
P < 0.001
1.0 (0.2)
P < 0.001
1.0 (0.2)
P < 0.001
0.8 (0.2)
P < 0.001
Age 0.4 (0.1)
P < 0.001
0.3 (0.1)
P = 0.001
0.3 (0.1)
P = 0.001
Systemic E2 0.01 (0.01)
P = 0.011
0.01 (0.01)
P = 0.064
Fat mass 0.3 (0.05)
P < 0.001
R2 for a model 0.367 0.709 0.749 0.828
DHT models
Intramuscular DHT 7.0 (11.8)
P = 0.563
15.1 (4.8)
P = 0.007
15.1 (4.6)
P = 0.005
13.5 (0.1)
P < 0.001
Age 0.6 (0.1)
P < 0.001
0.5 (0.1)
P < 0.001
0.5 (0.1)
P < 0.001
Systemic E2 0.01 (0.01)
P = 0.007
0.01 (0.01)
P = 0.044
Fat mass 0.3 (0.1)
P < 0.001
R2 for a model 0.031 0.664 0.714 0.802
DHEA models
Intramuscular DHEA 0.3 (0.1)
P < 0.001
0.2 (0.1)
P < 0.001
0.2 (0.2)
P < 0.001
0.2 (0.2)
P < 0.001
Age 0.4 (0.1)
P = 0.001
0.3 (0.1)
P = 0.003
0.3 (0.1)
P = 0.003
Systemic E2 0.01 (0.01)
P = 0.014
0.01 (0.01)
P = 0.068
Fat mass 0.3 (0.1)
P < 0.001
R2 for a model 0.371 0.696 0.734 0.831
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similar in both pre- and postmenopausal women regardless of their HRT
status. Only the intramuscular concentration of DHT was observed to be
different between study groups, being higher in both postmenopausal
groups as compared to the premenopausal women, which was
completely opposite to what has been observed for systemic DHT
concentration.
Intramuscular hormone levels were demonstrated to be significant
predictors of muscle performance explaining roughly 60% of the
variation in strength and 80% of the variation in power. This suggests
that tissue-specific steroid hormones and their local synthesis may have
functions which are independent from ovarian hormone secretion,
which would regulate, for example, reproductive functions. For brain,
the importance and independence of locally synthesized E2 has been
recently highlighted (Li et al., 2014). It has been shown that brain,
especially neurons, synthesizes E2 de novo from cholesterol, but
circulating E2 or precursor hormones also penetrate through the
blood–brain barrier (Kancheva et al., 2011). Therefore, the level of brain
E2 may deviate from the systemic levels, and the source of brain
(A) (D)
(B) (E)
(C) (F)
Fig. 2 E2 concentration (A) and gene
expressions (B, C, D, E, F) during
differentiation of mononucleated
myoblasts into multinucleated myotubes.
Gene expressions are normalized to the
expression of GAPDH and presented in
arbitrary units. E2, 17b-estradiol; ESR1,
estrogen receptor 1; ESR2, estrogen
receptor 2; GPER, G-protein-coupled
estrogen receptor 1; AR, androgen
receptor.
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hormones is not yet clear. Similar results have also been obtained for
adipose tissue (Belanger et al., 2002). Prior to the current study, the
intracrinology of skeletal muscle has been investigated only in a few
rodent (Aizawa et al., 2007, 2008, 2010, 2011) and human studies
(Vingren et al., 2008; P€oll€anen et al., 2011; Sato et al., 2014a,b). These
studies complemented by present study have clearly shown that skeletal
muscle is able to take up sex steroid hormones and their precursors and
is also able to locally synthesize biologically active hormones (T, E2, and
DHT) from their precursors. However, the regulation of hormone uptake
as well as the regulation and specific function of local, intramuscular
steroidogenesis remains to be elucidated. So far, only the role of
resistant exercise as a regulator of intramuscular steroidogenesis has
been studied, but the results were inconclusive. Vingren et al. (2008)
found no changes in intramuscular T synthesis after a single bout of
resistance exercise in young male and female subjects, while Sato et al.
found that 12 weeks of resistance training restored age-related differ-
(A)
(B)
(C) (E)
(D)
Fig. 3 The gene expressions of aromatase
(A) and sex steroid hormone receptors
(B, C, D, E) in myotubes exposed to female
serum. Gene expressions are normalized to
the expression of GAPDH and presented in
arbitrary units. ESR1, estrogen receptor 1;
ESR2, estrogen receptor 2; GPER, G-
protein-coupled estrogen receptor 1; AR,
androgen receptor.
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(A)
(B)
(C)
(D) (G)
(F)
(E)
Fig. 4 E2 (A) and T (B) concentration and
the gene expression of aromatase (C) and
steroid hormone receptors (D, E, F, G) in
myotubes exposed to E2. Gene expressions
are normalized to the expression of GAPDH
and presented in arbitrary units. E2, 17b-
estradiol; T, testosterone; ESR1, estrogen
receptor 1; ESR2, estrogen receptor 2;
GPER, G-protein-coupled estrogen receptor
1; AR, androgen receptor.
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ences in intramuscular DHEA and DHT in old male subjects (Sato et al.,
2014a). Our previous study (P€oll€anen et al., 2011) and the current one
found no age-related decrement in intramuscular sex steroid hormones
in female subjects over the studied age range. Contradictory results were
found by Sato et al. (2014a) for older men whose intramuscular DHEA,
free-T, and DHT levels were lower in old compared to young men, while
in our current study, there were no differences in intramuscular DHEA, T,
or E2 between old and young women, and higher intramuscular DHT
was found in older than younger women. Without larger studies
including both genders, we can only speculate whether this discrepancy
is a true gender difference due to differences in hormonal aging of men
and women. In addition to sex, there are also other differences in the
study populations between these two studies. For example, our young
group is in average over 10 years older and old group almost 10 years
(A)
(B)
(C)
(D) (H)
(G)
(F)
(E)
Fig. 5 Sex steroid hormone concentration
(A, B, C) and the gene expression of
aromatase (D) and steroid hormone
receptors (E, F, G, H) in myotubes exposed
to DHEA. Gene expressions are normalized
to the expression of GAPDH and presented
in arbitrary units. DHEA,
dehydroepiandrosterone; E2, 17b-estradiol;
T, testosterone; ESR1, estrogen receptor 1;
ESR2, estrogen receptor 2; GPER, G-
protein-coupled estrogen receptor 1; AR,
androgen receptor.
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younger than in Sato’s et al. study. Therefore, the age difference
between groups in our study was approximately 26 years, while in Sato’s
et al. study, it was approximately 43 years. It would require longitudinal
study or at least study using multiple age groups to be able to evaluate
whether and how intramuscular hormone concentrations change during
aging. In other words, we cannot be certain whether there is initial burst
of increase in intramuscular steroidogenesis after cessation of ovarian
steroidogenesis, which would later, with advancing age, decline. The
other clear discrepancy between these two studies is the difference in
the amount in total body fat between younger and older study groups.
In our study, the fat mass of study participants was fairly similar between
groups, while in Sato’s et al. study, there was significant difference
between young and old groups (body fat percentage 13.2% vs. 22.8%,
P < 0.01). As adipocytes are also capable of steroid synthesis and it has
been shown that increment in fat mass leads to decrement in the
muscular expression of steroidogenic enzymes (Sato et al., 2014b), it
cannot be ruled out that the higher amount of fat in older men would
not decrease the demand for intramuscular steroidogenesis. Current
study found intramuscular hormones to be associated with muscle
strength and power in women, which is in line with results obtained for
men (Sato et al., 2014a). However, we did not find the association
between muscle cross-sectional area and intramuscular hormones in
women as was found in men (Sato et al., 2014a).
Our results suggest that enzymes needed for local steroid synthesis
in muscle must be regulated by other mechanisms than by systemic
availability of hormones and that the uptake of systemic hormones to
muscle cells is probably actively regulated. We were able to show that
during in vitro differentiation of myoblasts into multinucleated myotu-
bes, gene expression of aromatase, ESR1, and AR was induced, but
that the cellular E2 concentration remains stable. The differences in the
hormone concentrations in premenopausal serum, and postmenopausal
nonusers’ or HRT users’ serum, did not affect the in vitro gene
expression of aromatase or AR, but did change the gene expression of
estrogen receptors ESR1, ESR2, and GPER in myotubes. The expression
levels were higher in the myotubes exposed to the postmenopausal
sera compared to premenopausal sera, suggesting that lower systemic
E2 levels may induce transcription of the estrogen receptors. This could
also, however, be due to other potential factors present in human sera.
Therefore, to circumvent this caveat, we used pure E2 to see whether it
is capable of mimicking the effects induced by female serum. The
myotubes did take up E2, but it did not have any significant effect on
gene expression. This finding further indicates that E2 does not directly
regulate the transcription of aromatase, an enzyme required for the
synthesis of E2 from its precursors or the transcription of steroid
hormone receptors. However, it does show that myotubes respond to
extracellular E2 and take it up, thereby indicating that some currently
unknown factor in sera or in the cellular niche present in vivo regulates
or inhibits spontaneous uptake of sex steroid hormones. Furthermore,
the precursor hormone DHEA was also taken up into the myotubes
which increased T and tended to increase the intracellular amount of
E2, demonstrating that steroidogenesis was activated in myotubes. In
addition, exposure to DHEA resulted in the transcriptional activation of
aromatase, but not of the hormone receptors. Therefore, it still remains
unclear as to how the transcription of steroid hormone receptors is
regulated and how signaling mediated by these receptors is activated in
skeletal muscle cells.
Skeletal muscle has recently been recognized as an endocrine organ
communicating with other organs by secreting vast amounts of proteins
and RNAs (Le Bihan et al., 2012). Currently, it is not known whether sex
steroid hormones produced by muscle cells contribute to the secretome
of muscle or function in an intra- or paracrine fashion within the muscle
cells. A limitation of the current and previous studies regarding
intramuscular steroidogenesis is the inability to identify the source of
the hormones which are measured both in the muscle tissue and in the
circulation. Therefore, we were not able to provide a clear consensus on
the amount of hormones taken up by the skeletal muscle cells or the
secretion of these hormones by the muscle fibers. In addition, we cannot
confirm whether the flux of these hormones or their synthesis is affected
by aging. Another limitation of the current study is the relatively small
number of study participants. However, when invasive sampling such as
muscle biopsies is required, the number of participants needs to be
minimized to follow ethical recommendations in avoiding unnecessary
discomfort and potential hazard caused to the participants. Limiting the
number of the participants is often a trade-off between doing
unnecessary invasive sampling and limiting the statistical power of a
study. Retrospectively, we were successful in avoiding both pitfalls by
finding highly significant associations between intramuscular sex steroid
hormones and skeletal muscle strength and power. The discordant twin
pair design is particularly suitable in this regard as the twins are matched
on age, genomic sequence, and multiple other shared factors from
childhood onwards, such that a small number of pairs have the statistical
power of a much larger study on unrelated individuals. This is particularly
true when the trait in question is under high genetic control, as
evidenced by the high degree of similarity in intramuscular hormones in
the MZ pairs.
Our results demonstrate that intramuscular sex steroids are involved
in the regulation of muscle strength and power. We have also recently
revealed the interaction between E2-responsive microRNAs (miR-182 and
-223) and IGF-1/AKT pathway (Olivieri et al., 2014), which is major
signaling pathway regulating muscle properties. The exposure of muscle
cells to E2 was shown to increase the phosphorylation of AKT and mTOR,
indicating higher activity of the pathway under higher E2 concentration.
Therefore, microRNA-mediated regulation of IGF-1/AKT pathway is a
potential molecular mechanism behind the intramuscular actions of
steroid hormones. As a consequence, interventions aiming to manipulate
intramuscular hormone synthesis may turn out to help to combat age-
related muscle weakness. However, the field of muscle intracrinology is
still in its infancy warranting further studies representing both genders
with different age groups and physical activity levels to provide a
consensus on the role and function of intracrine hormones in the
regulation of muscle performance.
Experimental procedures
Human study design and phenotype measurement
This study uses a subsample of a larger SAWEs Study (Ronkainen et al.,
2009; P€oll€anen et al., 2011) including postmenopausal HRT discordant
MZ twin pairs and a cohort of premenopausal women with no hormonal
treatment. Postmenopausal women were recruited from the Finnish
Twin cohort (Kaprio & Koskenvuo, 2002). From the HRT discordant MZ
twin pairs recruited to SAWEs, the current study utilizes data and
samples of eight pairs from whom one other sister was current user of
estrogen-containing HRT, while the other had never used HRT. The
median and interquartile range of the duration of the HRT was
6  5 years. Eight total body fat-matched premenopausal women were
selected from the age cohort of premenopausal women included in
SAWEs. Matching for body adiposity between groups was carried out to
avoid the possible influence of differences in the amount of adipogenic
steroidogenesis on the systemic or muscle specific effects under
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investigation. Fat and lean body mass were measured with the
multifrequency bioelectrical impedance analyzer (InBody 720; Biospace,
Seoul, Korea). Muscle strength, power, and size were assessed as
reported in Ronkainen et al. (2009). Briefly, isometric knee extension
strength was assessed with an adjustable dynamometer chair (Good
Strength; Metitur, Palokka, Finland). The explosive lower body muscle
power, that is, ability to produce force as quickly as possible, was
assessed as the maximum height that the participant was able to elevate
her body’s center of gravity during a vertical jump on a contact mat. In all
measurements, three to five trials were allowed and the maximal
performance was accepted as the result. Mid-thigh muscle CSA was
obtained using computed tomography scanner (Siemens Somatom
Emotion scanner; Siemens, Erlangen, Germany) taken from the midpoint
between the greater trochanter and the lateral joint line of the knee. Fat
infiltrated into the muscle compartment was excluded from the analysis.
Physical activity volume was retrospectively inferred using standard
questionnaire concerning previous 12 months and seven consecutive
days including leisure-time physical activity, daily activities such as
gardening, and commute physical activity from which the mean total
daily metabolic equivalent (MET) index was calculated as MET-h per day
(Finni et al., 2009). This study was approved by the Local Ethical
Committee of the Central Finland Hospital District (decision # E0606/06)
and performed following guidelines of the Helsinki declaration and good
clinical and scientific practice. All study participants signed an informed
consent form.
Serum and muscle sampling
Blood samples were taken between 07:00 and 09:00 h in standard
fasted conditions with participants in supine position. Sera were stored
at 80 °C until analysis. Directly following blood sampling, muscle
biopsies were taken from the mid-portion of the m. vastus lateralis from
all study participants using a standardized protocol. The blood samples
of premenopausal women were collected during 1–5 days of estrous
cycle. Visible blood and fat were removed before the biopsy sample was
snap-frozen in liquid nitrogen and stored at 80 °C until used for
mRNA, protein, or hormone analysis.
For the cell culture experiments, equal amounts of each serum sample
were pooled together to form either premenopausal serum, postmen-
opausal serum with HRT (HRT users), or postmenopausal serum without
HRT (HRT nonusers).
Systemic and intramuscular hormone measurements
Serum and muscle hormone assessments were carried out using the
protocols presented in P€oll€anen et al. (2011). Briefly, serum concentra-
tions of sex hormone-binding globulin (SHBG), DHEAS, follicle-stimulat-
ing hormone (FSH), and luteinizing hormone (LH) were measured using
solid-phase, chemiluminescent immunometric assays (Immulite 1000;
Diagnostic Products, Los Angeles, CA, USA). Serum E2 was determined
using an extraction radioimmunoassay, while T and DHT were measured
separately using LC-MS/MS. Muscle samples were homogenized on ice
in Tissue Extraction Reagent I (Invitrogen, Carlsbad, CA, USA) supple-
mented with protease and phosphatase inhibitors. The amount of total
soluble protein was determined using Pierce BCA Protein Assay kit
(Thermo Scientific, Rockford, IL, USA). Elisa tests were used to determine
E2, T, DHT, and DHEA concentrations in 1:10 diluted muscle superna-
tants in duplicates (IBL International, Hamburg, Germany). The concen-
trations of intramuscular hormones were expressed as nmol g1 soluble
muscle protein.
Cell culture experiments
Cell culture medium, fetal bovine serum (FBS), and antibiotics were
obtained from Life Technologies, Inc. (Carlsbad, CA, United States).
Phenol Red free DMEM was used in all experiments. Insulin and
apotransferrin were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Primary human muscle cell line was derived from a quadriceps
muscle biopsy of a 5-day-old female infant, in accordance with the
French legislation (Edom et al., 1994). The cells were maintained as
proliferating mononuclear myoblasts by cultivation in 4:1 DMEM:199
medium supplemented with 20% FBS, 1% sodium pyruvate,
100 U mL1 penicillin, and 100 lg mL1 streptomycin. To induce
differentiation into multinuclear myotubes, myoblasts were cultured in
differentiation medium containing 1:4 DMEM:199 supplemented with
1% sodium pyruvate, 10 lg mL1 insulin, 100 lg mL1 apotransferrin,
10 U mL1 penicillin, and 10 lg mL1 streptomycin. To study the
expression of steroid hormone receptors (ESR1, ESR2, GPER, and AR)
and aromatase (CYP19A1 gene) during the differentiation of myoblasts
into myotubes, the cells were harvested for RNA isolation either just
before switching to the differentiation medium (0 day sample) or after
every 24 h for 7 days (1–7 days samples). Three independent samples
were prepared for each time point. To investigate the effects of pre-
and postmenopausal serum with their inherent hormone status on
steroid hormone signaling, myotubes at day five were exposed to the
serum at final concentration of 10% v/v of differentiation medium.
Each serum pool contained equal amount of sera from eight partic-
ipants per group. Each exposure was performed in triplicates, and
exposed cells were collected for RNA isolation at 6-, 24-, and 72-h time
points after exposure. To investigate the effects of synthetic DHEA and
E2, myotubes differentiated for 5 days were exposed to 100 or 500 nM
DHEA, 10 or 100 nM E2, or mock for 6, 24, and 72 h before RNA
isolation. Mock was differentiation medium supplemented with etha-
nol, which was used as solvent for DHEA and E2. All experiments were
carried out in triplicate.
Quantitative PCR
NORGEN RNA kit (Miliot Science, Porvoo, Finland) was used to isolate
total RNA from cultured cells. RNA concentration was determined by
absorbance at 260 nm (NanoDrop ND-1000; Thermo Fisher Scientific
Inc., Waltham, MA, USA), and its purity was assessed based on a 260/
280 absorbance ratio of ~2.0. High-capacity cDNA Reverse Transcrip-
tion kit was used for cDNA synthesis (Applied Biosystems, Foster City,
CA, USA). Quantitative real-time PCR (qPCR) was performed according
to P€oll€anen et al. (2011).
Statistics
Results are presented as mean  standard deviation (SD) or median and
interquartile range (25th–75th percentile). Analyses were conducted
using STATA 13.0 (College Station, TX, USA). Statistical testing based on
individuals was conducted using methods (svy procedures) taking into
account the lack of statistical independence of twin sisters. The adjusted
Wald test or ANOVA followed by Tukey’s post hoc test were used to test
the significance of the differences between study groups and cell
exposures, respectively. Pearson’s correlation coefficient (r) and intraclass
correlation were calculated as a measure of within-pair similarity
between co-twins. Because MZ twin pairs are genetically identical, any
observed intrapair difference by definition is due to individual environ-
mental effects. Therefore, r can be taken as an estimate of the
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magnitude of genetic and environmental effects on tested variables.
Multivariate linear regression models were constructed to estimate the
association between intramuscular steroid hormones and muscle
strength, power, and cross-sectional area. It is known that muscle
variables are affected also by age, systemic E2, physical activity, and
potentially nutrition. In addition, adipose tissue is the potential source of
steroid hormones and may thereby affect intramuscular steroidogenesis.
Unfortunately, we did not have nutritional data available from the
premenopausal group. The association of these other potential con-
founders with muscle strength, power, and cross-sectional area was
investigated by bivariate linear regression to estimate the magnitude of
the association, and only the variables showing some independent
significant association with the muscle performance variables (Table S2,
Supporting information) were included step-by-step into the final models
(Tables 2, 3 and S1). Model 1 is a bivariate model showing the
association between the intramuscular hormone concentration and
muscle performance variable. Models 2–4 are multivariate models
including intramuscular hormone concentration and age, systemic E2
concentration, and total body fat mass incorporated one at the time. R2
shows coefficient of determination. The level of significance was set at
P ≤ 0.05.
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